Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies - LARVOL DELTA

Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous Photoaging (clinicaltrials.gov) - P1/2 | N=29 | Active, not recruiting | Sponsor: Stemedica Cell Technologies, Inc. | Suspended ➔ Active, not recruiting | Trial completion date: Dec 2022 ➔ Dec 2024 | Trial primary completion date: Apr 2022 ➔ Apr 2024

Enrollment closed • Trial completion date • Trial primary completion date • Dermatology • FGF • MMP1 • VEGFA

Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease (clinicaltrials.gov) - P2a | N=40 | Recruiting | Sponsor: Stemedica Cell Technologies, Inc. | Trial completion date: Jun 2023 ➔ Dec 2024 | Trial primary completion date: Dec 2022 ➔ Jul 2024

Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders • Dementia

A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19 (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: Stemedica Cell Technologies, Inc. | Trial completion date: Dec 2021 ➔ Dec 2022 | Trial primary completion date: Aug 2021 ➔ Sep 2022

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Mesenchymal stem cells in the treatment of severe COVID-19. (PubMed, Transl Med Commun) - No abstract available

Journal • Infectious Disease • Novel Coronavirus Disease

Stemedica Signs License Agreement with Pulthera, LLC for all Respiratory Indications including those related to COVID-19 (PRNewswire) - "Stemedica Cell Technologies, Inc....announced today that it has signed a Licensing Agreement with Pulthera, LLC for the rights to use, distribute and sell its mesenchymal stem cell technologies in the treatment of COVID-19 and additional pulmonary conditions....Pulthera anticipates advancing a multi-center trial in the treatment of those already afflicted with COVID-19, better known as 'Long Haulers Syndrome,' beginning late in 2021. These efforts will be coordinated in collaboration with the current FDA authorized Phase Ila clinical trial Stemedica has already begun for COVID-19 patients hospitalized with Acute Respiratory Distress Syndrome."

Licensing / partnership • New trial • Trial status • Infectious Disease • Novel Coronavirus Disease

A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19 (clinicaltrials.gov) - P2; N=40; Recruiting; Sponsor: Stemedica Cell Technologies, Inc.

Clinical • New P2 trial • Infectious Disease • Novel Coronavirus Disease

Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous Photoaging (clinicaltrials.gov) - P1/2; N=29; Suspended; Sponsor: Stemedica Cell Technologies, Inc.; Trial completion date: May 2019 ➔ Dec 2022; Trial primary completion date: Nov 2018 ➔ Apr 2022

Clinical • Trial completion date • Trial primary completion date • Dermatology • FGF • MMP1 • VEGFA

Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease (clinicaltrials.gov) - P2a; N=40; Recruiting; Sponsor: Stemedica Cell Technologies, Inc.; Trial completion date: Jun 2020 ➔ Jun 2023; Trial primary completion date: Dec 2019 ➔ Dec 2022

Clinical • Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders • Dementia

FDA Grants IND Approval for Phase II Clinical Trial Using Stemedica’s itMSC Therapy for COVID-19 Patients (PRNewswire) - P=NA, N=14; "Stemedica Cell Technologies, Inc. has received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) approval....The study will enroll up to 40 patients into two cohorts....Prior to submission of an IND, fourteen critically ill COVID-19 patients were treated on Emergency Use and Expanded Use INDs....The stem cell treatment resulted in an improved clinical course for the patients. Within 24-48 hours of receiving the stem cells, all patients had a significant reduction in oxygen requirements. Several patients went from an inability to talk or eat...to speaking in full sentences and eating full meals comfortably shortly after treatment.The study also found improved inflammatory modulation."

Clinical data • Cytokine storm • IND • New P2 trial • Infectious Disease • Novel Coronavirus Disease

A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure (clinicaltrials.gov) - P2a; N=23; Completed; Sponsor: CardioCell LLC; Active, not recruiting ➔ Completed

Clinical • Trial completion

Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease (clinicaltrials.gov) - P2a; N=40; Recruiting; Sponsor: Stemedica Cell Technologies, Inc.; Active, not recruiting ➔ Recruiting

Clinical • Enrollment open